Birchview Capital’s Castle Biosciences CSTL Stock Holding History

Birchview Capital’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$310K	Buy	12,984 +84	+0.7%	+$1.87K	0.14%	60
2026 Q1	$317K	Sell	12,900 -67,700	-84%	-$2.22M	0.18%	60
2025 Q4	$3.14M	Sell	80,600 -30,000	-27%	-$967K	1.84%	17
2025 Q3	$2.52M	Hold	110,600	–	–	1.9%	13
2025 Q2	$2.26M	Buy	110,600 +22,196	+25%	+$411K	2.24%	12
2025 Q1	$1.77M	Buy	88,404 +10,404	+13%	+$258K	1.54%	19
2024 Q4	$2.08M	Buy	78,000 +20,000	+34%	+$609K	1.69%	18
2024 Q3	$1.65M	Buy	58,000 +24,000	+71%	+$611K	1.43%	20
2024 Q2	$740K	Buy	34,000 +20,000	+143%	+$446K	0.68%	24
2024 Q1	$310K	Buy	14,000 +4,000	+40%	+$87K	0.25%	47
2023 Q4	$216K	Buy	+10,000	New	+$176K	0.17%	51

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Birchview Capital's CSTL Position: Q2 2026 in Review

Birchview Capital increased its Castle Biosciences (CSTL) stake by 0.65% in Q2 2026, buying an estimated $1.87K and bringing the position to 12,984 shares worth $310K. The position accounts for 0.14% of the portfolio, ranked #60.

Birchview Capital first reported a position in CSTL in Q4 2023 and has held it in 11 quarters since. The position peaked at $3.14M in Q4 2025. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

Birchview Capital held 12,984 shares of Castle Biosciences worth $310K as of Q2 2026.
Birchview Capital bought 84 Castle Biosciences shares in Q2 2026, an estimated $1.87K.
Castle Biosciences made up 0.14% of Birchview Capital's portfolio in Q2 2026, its #60 holding.
Birchview Capital first reported a position in Castle Biosciences in Q4 2023 and has held it in 11 quarters since.
Birchview Capital's Castle Biosciences position peaked at $3.14M in Q4 2025.
176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.